The disclosure provides a pharmaceutical composition of MOR receptor agonist. Specifically, the disclosure provides the pharmaceutical composition of MOR receptor agonist contains (1S,4S)-4-ethoxy-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine or its pharmaceutical salts and phosphate buffers. The pharmaceutical composition of the disclosure shows good stability after several months of storage.本披露中涉及一種MOR受體激動劑醫藥組成物。具體而言，本披露涉及的MOR受體激動劑醫藥組成物其包含(1S,4S)-4-甲氧基-N-(2-((R)-9-(吡啶-2-基)-6-氧雜螺[4.5]癸烷-9-基)乙基)-1,2,3,4-四氫萘-1-胺或其可藥用鹽，和磷酸鹽緩衝液。本披露中之醫藥組成物在儲存數月之後展現了良好的穩定性。
